Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-McNeil, J&J to Use Cellzome Proteomics Tech in Alzheimer s Research Program

NEW YORK, March 16 (GenomeWeb News) - Cellzome today said that it will collaborate with Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Pharmaceutical, in a drug-discovery research program for Alzheimer's disease.


Cellzome will apply its chemical proteomics technology to the program, and will receive a technology-access fee and research funding for two years. The company said it is also eligible for development milestone payments.


Ortho-McNeil will have exclusive worldwide rights to products developed during the collaboration and will pay Cellzome royalties on sales. J&JPRD will support the discovery research conducted at Cellzome, while Ortho-McNeil will be responsible for development, manufacturing, and commercialization of any drugs that result from the collaboration.


Cellzome said it will provide access to its existing Alzheimer's program technology, which includes an amyloid precursor protein processing pathway map and new drug targets. Ortho-McNeil will also have an option to license Cellzome's Gamma Secretase Modulator program, which Cellzome said includes novel small molecules for development as orally active treatments.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.